View in EDS

Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

Saved in:
Bibliographic Details
Title: Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
Authors: Contieri, R.1 (AUTHOR) contieri.ro@gmail.com, Mollica, V.2 (AUTHOR), Shariat, S.F.3 (AUTHOR), Pradere, B.4 (AUTHOR)
Source: Annals of Oncology. May2026, Vol. 37 Issue 5, p747-749. 3p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2026.01.003